Percheron Therapeutics Limited has released a press release.
Completion of avicursen (ATL1102) toxicology study
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Phase IIb study of ATL1102 in DMD completes recruitment
- Receipt of R&D Tax incentive payment
- Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
- Antisense Share Purchase Plan (SPP) Raises $3.26 Million
- Share Purchase Plan (SPP) Offer Booklet
Later from Percheron Therapeutics
- $13.0 million Institutional Placement
- Percheron to launch Share Purchase Plan
- Results of Share Purchase Plan
- Clinical Trial Update
- Topline Six-Month Results From Phase IIb Study of Avicursen
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics